Posted by Michael Wonder on 30 Jun 2021
Allogene Therapeutics granted FDA fast track designation for ALLO-605, the first TurboCAR T Cell therapy, for the treatment of relapsed/refractory multiple myeloma
30 June 2021 - TurboCAR technology provides selective, programmable cytokine signaling designed to improve function and potency of AlloCAR T cells.
Allogene Therapeutics today announced that the U.S. FDA has granted fast track designation to ALLO-605, the Company’s next-generation AlloCAR T therapy targeting BCMA for the treatment of relapsed or refractory multiple myeloma.
